DSM Biologics and UMN Pharma, Inc. have signed a biopharmaceutical manufacturing agreement based on the PER.C6 platform. Under the terms of the agreement DSM Biologics will provide UMN Pharma with full process and analytical development services and cGMP manufacturing batches for UMN’s fusion protein, UMN-03, for the treatment of muscular dystrophy and metabolic diseases. The services will be provided out of DSM Biologics’ FDA-approved manufacturing facility in Groningen. The agreement follows t...